Revlimid
Showing 26 - 50 of 598
CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)
Recruiting
- CNS Lymphoma
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 10, 2022
Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL Trial in Houston (Mosunetuzumab, Polatuzumab vedotin, Tafasitamab)
Not yet recruiting
- Hodgkin Lymphoma
- +2 more
- Mosunetuzumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Nov 7, 2022
Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Epcoritamab
- Lenalidomide
- (no location specified)
Jan 20, 2023
Multiple Myeloma Trial in United States (KRdD followed by auto-HCT, KRdD only)
Active, not recruiting
- Multiple Myeloma
- KRdD followed by auto-HCT
- KRdD only
-
Birmingham, Alabama
- +3 more
Mar 26, 2022
Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia Trial in Houston (Laboratory Biomarker
Completed
- Alkylating Agent-Related Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Laboratory Biomarker Analysis
- Lenalidomide
-
Houston, TexasM D Anderson Cancer Center
Oct 18, 2022
Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,
Recruiting
- Multiple Myeloma
- +2 more
- Daratumumab
- +10 more
-
Wuhan, Hubei, ChinaInstitute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023
Leukemia, Lymphoma Trial in Houston (Rituximab, Lenalidomide)
Active, not recruiting
- Leukemia
- Lymphoma
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Oct 11, 2022
CNS Tumors Trial in Saint Petersburg (25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®), 50 mg/m2
Terminated
- Central Nervous System Tumors
- 25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
- +4 more
-
Saint Petersburg, FloridaJohns Hopkins All Childen's Hospital
Mar 8, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Tampa (High Dose Methylprednisolone (HDMP), Ofatumumab,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- High Dose Methylprednisolone (HDMP)
- +2 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 12, 2023
Multiple Myeloma Trial in Rochester (Daratumumab, Lenalidomide, Dexamethasone)
Recruiting
- Multiple Myeloma
- Daratumumab
- +2 more
-
Rochester, New YorkUniversity of Rochester Medical Center
Jul 8, 2022
Multiple Myeloma Trial in Atlanta (Bortezomib, Lenalidomide, Dexamethasone)
Completed
- Multiple Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Winship Cancer Institute
Nov 1, 2021
Multiple Myeloma Trial in New York (Clarithromycin, Lenalidomide, Dexamethasone)
Completed
- Multiple Myeloma
- Clarithromycin, Lenalidomide, Dexamethasone
-
New York, New YorkWeill Medical College of Cornell University
May 26, 2021
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma (MZL)
- Odronextamab
- +2 more
-
Chiang Mai, ThailandChiang Mai University
Nov 20, 2023
Plasma Cell Myeloma Trial in Buffalo (Belantamab Mafodotin, Lenalidomide)
Recruiting
- Plasma Cell Myeloma
- Belantamab Mafodotin
- Lenalidomide
-
Buffalo, New YorkRoswell Park Cancer Institute
Dec 5, 2022
Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma
- Zanubrutinib
- +3 more
-
Westbury, New YorkClinical Research Alliance, Inc.
Nov 14, 2022
Plasma Cell Myeloma, Transplant-Related Carcinoma Trial in Seattle (Ixazomib Citrate, Laboratory Biomarker Analysis,
Active, not recruiting
- Plasma Cell Myeloma
- Transplant-Related Carcinoma
- Ixazomib Citrate
- +2 more
-
Seattle, WashingtonFred Hutchinson Cancer Research Center
Jul 12, 2022
Multiple Myeloma Trial in Shanghai (Selinexor, Thalidomide, Lenalidomide)
Recruiting
- Multiple Myeloma
- Selinexor
- +4 more
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Mar 3, 2022
Smoldering Multiple Myeloma Trial in Boston (Ixazomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Smoldering Multiple Myeloma
- Ixazomib
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 15, 2022
Lenalidomide / Dexamethasone as First Line Therapy in Multiple
Active, not recruiting
- Multiple Myeloma
-
Bochum, GermanyHämatologisch-Onkologische Schwerpunktpraxis
Feb 1, 2022
High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- High-risk Smoldering Multiple Myeloma
- Multiple Myeloma
- Daratumumab
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 18, 2021
Multiple Myeloma Trial in Little Rock (Carfilzomib, Thalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib
- +11 more
-
Little Rock, ArkansasUniversity of Arkansas for Medical Sciences
Sep 1, 2022